盐酸曲美他嗪治疗冠心病稳定型心绞痛的临床治疗疗效分析

Clinical Effect of Trimetazidine Hydrochloride on Coronary Heart Disease Stable Angina Pectoris

目的探究对冠心病稳定型心绞痛患者采取盐酸曲美他嗪治疗的临床效果。方法选取在2017年9月—2019年10月期间在该院进行治疗的100例冠心病稳定型心绞痛患者,采用数字随机表法将其分为对照组(n=50)和研究组(n=50)。对照组的患者给予常规治疗方式,研究组的患者给予盐酸曲美他嗪治疗,对两组患者的血脂水平情况、心绞痛发作次数、发作持续时间情况、不良反应发生情况、心电图指数情况以及治疗有效率进行比较分析。结果治疗后,对照组TG、TC、TDL、HDL分别为(1.87±0.43)mmol/L、(5.03±0.41)、mmol/L(3.72±0.15)mmol/L、(1.33±0.29)mmol/L,研究组TG、TC、TDL、HDL分别为(1.26±0.17)mmol/L、(4.27±0.83)mmol/L、(3.02±0.65)mmol/L、(1.79±0.16)mmol/L(t=9.328、5.805、7.420、9.821,P<0.05);对照组STmax、∑ST、NST指数分别为(0.66±0.34)、(1.88±1.05)mV、(2.64±1.22)个,研究组分别为(0.43±0.22)mV、(1.03±1.12)mV、(2.11±1.02)个(t=4.016、3.915、2.357,P<0.05);心绞痛发作次数分别为(4.32±0.68)次、(3.26±0.84)次(t=6.935,P<0.05);发作持续时间分别为(2.33±0.49)min、(1.28±0.16)min(t=14.404,P<0.05);研究组不良反应发生率4%明显低于对照组20%(χ2=6.061,P<0.05);研究组治疗有效率96%明显高于对照组84%(χ2=4.000,P<0.05)。结论对冠心病稳定型心绞痛患者采取盐酸曲美他嗪治疗可有效改善冠心病稳定性心绞痛的临床症状,提高治疗有效率,值得临床推荐与应用。

Objective To investigate the clinical effect of trimetazidine hydrochloride on patients with stable angina pectoris of coronary heart disease.Methods 100 patients with stable angina pectoris treated in our hospital between September 2017 and October 2019 were selected and divided into a control group(n=50)and a research group(n=50).The patients in the control group were given conventional treatment,and the patients in the study group were treated with trimetazidine hydrochloride.The blood lipid levels,the number of angina attacks,the duration of attacks,the occurrence of adverse reactions,the status of electrocardiogram index,and the treatment efficiency were compared and analyzed.Results After treatment,the TG,TC,TDL and HDL of the control group were(1.87±0.43)mmol/L,(5.03±0.41)mmol/L,(3.72±0.15)mmol/L,(1.33±0.29)mmol/L,and the TG,TC,TDL and HDL of the study group were(1.26±0.17)mmol/L,(4.27±0.83)mmol/L,(3.02±0.65)mmol/L,(1.79±0.16)mmol/L,(t=9.328,5.805,7.420,9.821,P<0.05);control group STmax,∑ST,NST index were(0.66±0.34)mV,(1.88±1.05)mV,(2.64±1.22),the research group were(0.43±0.22)mV,(1.03±1.12)mV,(2.11±1.02)(t=4.016,3.915,2.357,P<0.05);the number of angina attacks were(4.32±0.68)times,(3.26±0.84)times(t=6.935,P<0.05);the duration of attacks was(2.33±0.49)min,(1.28±0.16)min(t=14.404,P<0.05);the incidence of adverse reactions in the study group was 4%,which was significantly lower than that in the control group 20%(χ2=6.061,P<0.05);the treatment effective rate in the study group was 96%,which was significantly higher than that in the control group,84%(χ2=4.000,P<0.05).Conclusion The treatment of trimetazidine hydrochloride in patients with stable angina pectoris of coronary heart disease can effectively improve the clinical symptoms of coronary heart disease angina pectoris and improve the treatment efficiency.It is worthy of clinical recommendation and application.